Zentalis Pharmaceuticals Inc
For the period ended Jun 30, 2024. Filed Aug 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 9, 2024
ZNTL$1.80+3.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(In thousands, except per share amounts)
| Three Months EndedJune 30, | Six Months EndedJune 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| License Revenue | $— | $— | $40,560 | $— |
| Operating Expenses | ||||
| Research and development | 48,386 | 42,684 | $97,971 | $91,268 |
| Zentera in-process research and development | — | 45,568 | — | 45,568 |
| General and administrative | 16,762 | 15,664 | 32,502 | 32,033 |
| Total operating expenses | 65,148 | 103,916 | 130,473 | 168,869 |
| Loss from operations | (65,148) | (103,916) | (89,913) | (168,869) |
| Other Income (Expense) | ||||
| Investment and other income (expense), net | (22,863) | 4,451 | 12,085 | 8,560 |
| Net loss before income taxes | (88,011) | (99,465) | (77,828) | (160,309) |
| Income tax expense (benefit) | 266 | (605) | 409 | (497) |
| Loss on equity method investment | — | 13,704 | — | 16,014 |
| Net loss | (88,277) | (112,564) | (78,237) | (175,826) |
| Net loss attributable to noncontrolling interests | — | (37) | (28) | (80) |
| Net loss attributable to Zentalis | $(88,277) | $(112,527) | $(78,209) | $(175,746) |
| Net loss per common share outstanding, basic and diluted | $(1.24) | $(1.85) | $(1.10) | $(2.93) |
| Common shares used in computing net loss per share, basic and diluted | 71,040 | 60,790 | 70,969 | 60,038 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.